{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:44:32Z","timestamp":1792813472336,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dysfunction of NMDA receptor (NMDAR)-mediated transmission is supposed to contribute to the motor and non-motor symptoms of Parkinson\u2019s Disease (PD), and to L-DOPA-induced dyskinesia. Besides the main agonist L-glutamate, two other amino acids in the atypical D-configuration, D-serine and D-aspartate, activate NMDARs. In the present work, we investigated the effect of dopamine depletion on D-amino acids metabolism in the brain of MPTP-lesioned <jats:italic>Macaca mulatta<\/jats:italic>, and in the serum and cerebrospinal fluid of PD patients. We found that MPTP treatment increases D-aspartate and D-serine in the monkey putamen while L-DOPA rescues both D-amino acids levels. Conversely, dopaminergic denervation is associated with selective D-serine reduction in the <jats:italic>substantia nigra<\/jats:italic>. Such decrease suggests that the beneficial effect of D-serine adjuvant therapy previously reported in PD patients may derive from the normalization of endogenous D-serine levels and consequent improvement of nigrostriatal hypoglutamatergic transmission at glycine binding site. We also found reduced D-serine concentration in the cerebrospinal fluid of L-DOPA-free PD patients. These results further confirm the existence of deep interaction between dopaminergic and glutamatergic neurotransmission in PD and disclose a possible direct influence of D-amino acids variations in the changes of NMDAR transmission occurring under dopamine denervation and L-DOPA therapy.<\/jats:p>","DOI":"10.1038\/s41598-019-45419-1","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:03:04Z","timestamp":1561024984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson\u2019s disease patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Tommaso","family":"Nuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Punzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Devoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Paciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-2561","authenticated-orcid":false,"given":"Silvia","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Thiolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"V\u00e9ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolo","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Gardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-7243","authenticated-orcid":false,"given":"Loredano","family":"Pollegioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-4638","authenticated-orcid":false,"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Usiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"45419_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cortex.2017.06.006","volume":"94","author":"I Obeso","year":"2017","unstructured":"Obeso, I. et al. Unilateral subthalamotomy in Parkinson\u2019s disease: Cognitive, psychiatric and neuroimaging changes. Cortex 94, 39\u201348, https:\/\/doi.org\/10.1016\/j.cortex.2017.06.006 (2017).","journal-title":"Cortex"},{"key":"45419_CR2","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat Rev Dis Primers 3, 17013, https:\/\/doi.org\/10.1038\/nrdp.2017.13 (2017).","journal-title":"Nat Rev Dis Primers"},{"key":"45419_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt, P. A. Levodopa therapy for Parkinson\u2019s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64\u201372, https:\/\/doi.org\/10.1002\/mds.26082 (2015).","journal-title":"Mov Disord"},{"key":"45419_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide, M. F. et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease. Prog Neurobiol 132, 96\u2013168, https:\/\/doi.org\/10.1016\/j.pneurobio.2015.07.002 (2015).","journal-title":"Prog Neurobiol"},{"key":"45419_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/archneur.64.1.20","volume":"64","author":"MR DeLong","year":"2007","unstructured":"DeLong, M. R. & Wichmann, T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 64, 20\u201324, https:\/\/doi.org\/10.1001\/archneur.64.1.20 (2007).","journal-title":"Arch Neurol"},{"key":"45419_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/brain\/awr028","volume":"134","author":"I Ahmed","year":"2011","unstructured":"Ahmed, I. et al. Glutamate NMDA receptor dysregulation in Parkinson\u2019s disease with dyskinesias. Brain 134, 979\u2013986, https:\/\/doi.org\/10.1093\/brain\/awr028 (2011).","journal-title":"Brain"},{"key":"45419_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fncel.2015.00025","volume":"9","author":"F Gardoni","year":"2015","unstructured":"Gardoni, F. & Bellone, C. Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases. Front Cell Neurosci 9, 25, https:\/\/doi.org\/10.3389\/fncel.2015.00025 (2015).","journal-title":"Front Cell Neurosci"},{"key":"45419_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00702-018-1846-8","volume":"125","author":"M Mellone","year":"2018","unstructured":"Mellone, M. & Gardoni, F. Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications. J Neural Transm (Vienna) 125, 1225\u20131236, https:\/\/doi.org\/10.1007\/s00702-018-1846-8 (2018).","journal-title":"J Neural Transm (Vienna)"},{"key":"45419_CR9","unstructured":"Calabresi, P., Giacomini, P., Centonze, D. & Bernardi, G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 47, S60\u201368; discussion S68\u201369 (2000)."},{"key":"45419_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","volume":"48","author":"PJ Hallett","year":"2005","unstructured":"Hallett, P. J. et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease. Neuropharmacology 48, 503\u2013516, https:\/\/doi.org\/10.1016\/j.neuropharm.2004.11.008 (2005).","journal-title":"Neuropharmacology"},{"key":"45419_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/187152709789824606","volume":"8","author":"KA Johnson","year":"2009","unstructured":"Johnson, K. A., Conn, P. J. & Niswender, C. M. Glutamate receptors as therapeutic targets for Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 8, 475\u2013491 (2009).","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"45419_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mds.25096","volume":"28","author":"P Calabresi","year":"2013","unstructured":"Calabresi, P. et al. New synaptic and molecular targets for neuroprotection in Parkinson\u2019s disease. Mov Disord 28, 51\u201360, https:\/\/doi.org\/10.1002\/mds.25096 (2013).","journal-title":"Mov Disord"},{"key":"45419_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","volume":"102","author":"PJ Hallett","year":"2004","unstructured":"Hallett, P. J. & Standaert, D. G. Rationale for and use of NMDA receptor antagonists in Parkinson\u2019s disease. Pharmacol Ther 102, 155\u2013174, https:\/\/doi.org\/10.1016\/j.pharmthera.2004.04.001 (2004).","journal-title":"Pharmacol Ther"},{"key":"45419_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.tins.2006.06.008","volume":"29","author":"M Martineau","year":"2006","unstructured":"Martineau, M., Baux, G. & Mothet, J. P. D-serine signalling in the brain: friend and foe. Trends Neurosci 29, 481\u2013491, https:\/\/doi.org\/10.1016\/j.tins.2006.06.008 (2006).","journal-title":"Trends Neurosci"},{"key":"45419_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.tins.2016.09.007","volume":"39","author":"H Wolosker","year":"2016","unstructured":"Wolosker, H., Balu, D. T. & Coyle, J. T. The Rise and Fall of the d-Serine-Mediated Gliotransmission Hypothesis. Trends Neurosci 39, 712\u2013721, https:\/\/doi.org\/10.1016\/j.tins.2016.09.007 (2016).","journal-title":"Trends Neurosci"},{"key":"45419_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3389\/fpsyt.2018.00559","volume":"9","author":"F Errico","year":"2018","unstructured":"Errico, F., Nuzzo, T., Carella, M., Bertolino, A. & Usiello, A. The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies. Front Psychiatry 9, 559, https:\/\/doi.org\/10.3389\/fpsyt.2018.00559 (2018).","journal-title":"Front Psychiatry"},{"key":"45419_CR17","first-page":"113","volume":"31","author":"F Salvatore","year":"1966","unstructured":"Salvatore, F., Zappia, V. & Cortese, R. Studies on the deamination of L-amino acids in mammalian tissues. Enzymologia 31, 113\u2013127 (1966).","journal-title":"Enzymologia"},{"key":"45419_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/191705a0","volume":"191","author":"F Salvatore","year":"1961","unstructured":"Salvatore, F. & Bocchini, V. Prevention of ammonia toxicity by amino-acids concerned in the biosynthesis of urea. Nature 191, 705\u2013706 (1961).","journal-title":"Nature"},{"key":"45419_CR19","doi-asserted-by":"publisher","first-page":"10168","DOI":"10.1523\/JNEUROSCI.0524-15.2015","volume":"35","author":"BE Herring","year":"2015","unstructured":"Herring, B. E., Silm, K., Edwards, R. H. & Nicoll, R. A. Is Aspartate an Excitatory Neurotransmitter? J Neurosci 35, 10168\u201310171, https:\/\/doi.org\/10.1523\/JNEUROSCI.0524-15.2015 (2015).","journal-title":"J Neurosci"},{"key":"45419_CR20","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s00018-010-0307-9","volume":"67","author":"L Pollegioni","year":"2010","unstructured":"Pollegioni, L. & Sacchi, S. Metabolism of the neuromodulator D-serine. Cell Mol Life Sci 67, 2387\u20132404, https:\/\/doi.org\/10.1007\/s00018-010-0307-9 (2010).","journal-title":"Cell Mol Life Sci"},{"key":"45419_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1073\/pnas.96.2.721","volume":"96","author":"H Wolosker","year":"1999","unstructured":"Wolosker, H. et al. Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA 96, 721\u2013725 (1999).","journal-title":"Proc Natl Acad Sci USA"},{"key":"45419_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fmolb.2017.00088","volume":"4","author":"G Murtas","year":"2017","unstructured":"Murtas, G., Sacchi, S., Valentino, M. & Pollegioni, L. Biochemical Properties of Human D-Amino Acid Oxidase. Front Mol Biosci 4, 88, https:\/\/doi.org\/10.3389\/fmolb.2017.00088 (2017).","journal-title":"Front Mol Biosci"},{"key":"45419_CR23","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00726-012-1345-4","volume":"43","author":"S Sacchi","year":"2012","unstructured":"Sacchi, S., Caldinelli, L., Cappelletti, P., Pollegioni, L. & Molla, G. Structure-function relationships in human D-amino acid oxidase. Amino Acids 43, 1833\u20131850, https:\/\/doi.org\/10.1007\/s00726-012-1345-4 (2012).","journal-title":"Amino Acids"},{"key":"45419_CR24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/cbdv.200900250","volume":"7","author":"M Katane","year":"2010","unstructured":"Katane, M. & Homma, H. D-aspartate oxidase: the sole catabolic enzyme acting on free D-aspartate in mammals. Chem Biodivers 7, 1435\u20131449, https:\/\/doi.org\/10.1002\/cbdv.200900250 (2010).","journal-title":"Chem Biodivers"},{"key":"45419_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neuint.2015.07.005","volume":"88","author":"A El Arfani","year":"2015","unstructured":"El Arfani, A. et al. Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson\u2019s disease. Neurochem Int 88, 88\u201396, https:\/\/doi.org\/10.1016\/j.neuint.2015.07.005 (2015).","journal-title":"Neurochem Int"},{"key":"45419_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/jssc.200800459","volume":"32","author":"S Li","year":"2009","unstructured":"Li, S., Yu, Q., Lu, X. & Zhao, S. Determination of D,L-serine in midbrain of Parkinson\u2019s disease mouse by capillary electrophoresis with in-column light-emitting diode induced fluorescence detection. J Sep Sci 32, 282\u2013287, https:\/\/doi.org\/10.1002\/jssc.200800459 (2009).","journal-title":"J Sep Sci"},{"key":"45419_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1755-5949.2011.00275.x","volume":"17","author":"M Lu","year":"2011","unstructured":"Lu, M. et al. Potentiation of D-serine involves degeneration of dopaminergic neurons in MPTP\/p mouse model of Parkinson\u2019s disease. CNS Neurosci Ther 17, 796\u2013798, https:\/\/doi.org\/10.1111\/j.1755-5949.2011.00275.x (2011).","journal-title":"CNS Neurosci Ther"},{"key":"45419_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1017\/S1461145711001015","volume":"15","author":"E Gelfin","year":"2012","unstructured":"Gelfin, E. et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson\u2019s disease. Int J Neuropsychopharmacol 15, 543\u2013549, https:\/\/doi.org\/10.1017\/S1461145711001015 (2012).","journal-title":"Int J Neuropsychopharmacol"},{"key":"45419_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/pcn.12175","volume":"68","author":"CH Tsai","year":"2014","unstructured":"Tsai, C. H. et al. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson\u2019s disease with dementia. Psychiatry Clin Neurosci 68, 692\u2013700, https:\/\/doi.org\/10.1111\/pcn.12175 (2014).","journal-title":"Psychiatry Clin Neurosci"},{"key":"45419_CR30","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1523\/JNEUROSCI.3881-15.2016","volume":"36","author":"D Punzo","year":"2016","unstructured":"Punzo, D. et al. Age-Related Changes in D-Aspartate Oxidase Promoter Methylation Control Extracellular D-Aspartate Levels and Prevent Precocious Cell Death during Brain Aging. J Neurosci 36, 3064\u20133078, https:\/\/doi.org\/10.1523\/JNEUROSCI.3881-15.2016 (2016).","journal-title":"J Neurosci"},{"key":"45419_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.expneurol.2011.09.013","volume":"232","author":"F Errico","year":"2011","unstructured":"Errico, F. et al. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia. Exp Neurol 232, 240\u2013250, https:\/\/doi.org\/10.1016\/j.expneurol.2011.09.013 (2011).","journal-title":"Exp Neurol"},{"key":"45419_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/exnr.2002.7891","volume":"175","author":"R Deumens","year":"2002","unstructured":"Deumens, R., Blokland, A. & Prickaerts, J. Modeling Parkinson\u2019s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175, 303\u2013317, https:\/\/doi.org\/10.1006\/exnr.2002.7891 (2002).","journal-title":"Exp Neurol"},{"key":"45419_CR33","doi-asserted-by":"publisher","first-page":"a009308","DOI":"10.1101\/cshperspect.a009308","volume":"2","author":"G Porras","year":"2012","unstructured":"Porras, G., Li, Q. & Bezard, E. Modeling Parkinson\u2019s disease in primates: The MPTP model. Cold Spring Harb Perspect Med 2, a009308, https:\/\/doi.org\/10.1101\/cshperspect.a009308 (2012).","journal-title":"Cold Spring Harb Perspect Med"},{"key":"45419_CR34","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1093\/cercor\/bhu076","volume":"25","author":"M Engeln","year":"2015","unstructured":"Engeln, M., De Deurwaerdere, P., Li, Q., Bezard, E. & Fernagut, P. O. Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cereb Cortex 25, 2783\u20132792, https:\/\/doi.org\/10.1093\/cercor\/bhu076 (2015).","journal-title":"Cereb Cortex"},{"key":"45419_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep03730","volume":"4","author":"G Porras","year":"2014","unstructured":"Porras, G. et al. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep 4, 3730, https:\/\/doi.org\/10.1038\/srep03730 (2014).","journal-title":"Sci Rep"},{"key":"45419_CR36","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1471-4159.1993.tb13657.x","volume":"61","author":"ML Chouinard","year":"1993","unstructured":"Chouinard, M. L., Gaitan, D. & Wood, P. L. Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, D-serine, in human temporal cortex: comparison of normal, Parkinson, and Alzheimer tissues. J Neurochem 61, 1561\u20131564 (1993).","journal-title":"J Neurochem"},{"key":"45419_CR37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1162\/0898929054475226","volume":"17","author":"A Talati","year":"2005","unstructured":"Talati, A. & Hirsch, J. Functional specialization within the medial frontal gyrus for perceptual go\/no-go decisions based on \u201cwhat,\u201d \u201cwhen,\u201d and \u201cwhere\u201d related information: an fMRI study. J Cogn Neurosci 17, 981\u2013993, https:\/\/doi.org\/10.1162\/0898929054475226 (2005).","journal-title":"J Cogn Neurosci"},{"key":"45419_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnsyn.2014.00014","volume":"6","author":"J Sasabe","year":"2014","unstructured":"Sasabe, J., Suzuki, M., Imanishi, N. & Aiso, S. Activity of D-amino acid oxidase is widespread in the human central nervous system. Front Synaptic Neurosci 6, 14, https:\/\/doi.org\/10.3389\/fnsyn.2014.00014 (2014).","journal-title":"Front Synaptic Neurosci"},{"key":"45419_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0278-5846(01)00237-8","volume":"26","author":"F Calon","year":"2002","unstructured":"Calon, F. et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26, 127\u2013138 (2002).","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"45419_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","volume":"73","author":"N Morin","year":"2013","unstructured":"Morin, N. et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 73, 216\u2013231, https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.028 (2013).","journal-title":"Neuropharmacology"},{"key":"45419_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fncel.2015.00245","volume":"9","author":"M Mellone","year":"2015","unstructured":"Mellone, M. et al. NMDA receptor GluN2A\/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. Front Cell Neurosci 9, 245, https:\/\/doi.org\/10.3389\/fncel.2015.00245 (2015).","journal-title":"Front Cell Neurosci"},{"key":"45419_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/syn.20739","volume":"64","author":"MA Silverdale","year":"2010","unstructured":"Silverdale, M. A. et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 64, 177\u2013180, https:\/\/doi.org\/10.1002\/syn.20739 (2010).","journal-title":"Synapse"},{"key":"45419_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0197-0186(98)00034-5","volume":"33","author":"KK Yung","year":"1998","unstructured":"Yung, K. K. Localization of ionotropic and metabotropic glutamate receptors in distinct neuronal elements of the rat substantia nigra. Neurochem Int 33, 313\u2013326 (1998).","journal-title":"Neurochem Int"},{"key":"45419_CR44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2014.10.011","volume":"20","author":"F Gardoni","year":"2015","unstructured":"Gardoni, F. & Di Luca, M. Targeting glutamatergic synapses in Parkinson\u2019s disease. Curr Opin Pharmacol 20, 24\u201328, https:\/\/doi.org\/10.1016\/j.coph.2014.10.011 (2015).","journal-title":"Curr Opin Pharmacol"},{"key":"45419_CR45","doi-asserted-by":"publisher","first-page":"14182","DOI":"10.1523\/JNEUROSCI.2149-10.2010","volume":"30","author":"V Paille","year":"2010","unstructured":"Paille, V. et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30, 14182\u201314193, https:\/\/doi.org\/10.1523\/JNEUROSCI.2149-10.2010 (2010).","journal-title":"J Neurosci"},{"key":"45419_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","volume":"96","author":"V Sgambato-Faure","year":"2012","unstructured":"Sgambato-Faure, V. & Cenci, M. A. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson\u2019s disease. Prog Neurobiol 96, 69\u201386, https:\/\/doi.org\/10.1016\/j.pneurobio.2011.10.005 (2012).","journal-title":"Prog Neurobiol"},{"key":"45419_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/mds.25306","volume":"28","author":"U Heresco-Levy","year":"2013","unstructured":"Heresco-Levy, U., Shoham, S. & Javitt, D. C. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson\u2019s disease: a hypothesis. Mov Disord 28, 419\u2013424, https:\/\/doi.org\/10.1002\/mds.25306 (2013).","journal-title":"Mov Disord"},{"key":"45419_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF01345244","volume":"14","author":"A Cheramy","year":"1998","unstructured":"Cheramy, A., L\u2019Hirondel, M., Godeheu, G., Artaud, F. & Glowinski, J. Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Amino Acids 14, 63\u201368 (1998).","journal-title":"Amino Acids"},{"key":"45419_CR49","doi-asserted-by":"publisher","unstructured":"Shimizu, S. et al. Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway. Int J Mol Sci 18 https:\/\/doi.org\/10.3390\/ijms18071416 (2017).","DOI":"10.3390\/ijms18071416"},{"key":"45419_CR50","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1085\/jgp.201812032","volume":"150","author":"KB Hansen","year":"2018","unstructured":"Hansen, K. B. et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol 150, 1081\u20131105, https:\/\/doi.org\/10.1085\/jgp.201812032 (2018).","journal-title":"J Gen Physiol"},{"key":"45419_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1515\/revneuro-2014-0053","volume":"26","author":"X Zhou","year":"2015","unstructured":"Zhou, X., Chen, Z., Yun, W. & Wang, H. NMDA receptor activity determines neuronal fate: location or number? Rev Neurosci 26, 39\u201347, https:\/\/doi.org\/10.1515\/revneuro-2014-0053 (2015).","journal-title":"Rev Neurosci"},{"key":"45419_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz, J. T. et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 121, 125\u2013130, https:\/\/doi.org\/10.1016\/j.schres.2010.05.012 (2010).","journal-title":"Schizophr Res"},{"key":"45419_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fpsyt.2018.00091","volume":"9","author":"WY Hsu","year":"2018","unstructured":"Hsu, W. Y., Lane, H. Y. & Lin, C. H. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer\u2019s Disease, and Parkinson\u2019s Disease. Front Psychiatry 9, 91, https:\/\/doi.org\/10.3389\/fpsyt.2018.00091 (2018).","journal-title":"Front Psychiatry"},{"key":"45419_CR54","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.1073\/pnas.81.21.6876","volume":"81","author":"GE Fagg","year":"1984","unstructured":"Fagg, G. E. & Matus, A. Selective association of N-methyl aspartate and quisqualate types of L-glutamate receptor with brain postsynaptic densities. Proc Natl Acad Sci USA 81, 6876\u20136880 (1984).","journal-title":"Proc Natl Acad Sci USA"},{"key":"45419_CR55","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1073\/pnas.97.9.4926","volume":"97","author":"JP Mothet","year":"2000","unstructured":"Mothet, J. P. et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 97, 4926\u20134931 (2000).","journal-title":"Proc Natl Acad Sci USA"},{"key":"45419_CR56","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1523\/JNEUROSCI.10-07-02385.1990","volume":"10","author":"DK Patneau","year":"1990","unstructured":"Patneau, D. K. & Mayer, M. L. Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors. J Neurosci 10, 2385\u20132399 (1990).","journal-title":"J Neurosci"},{"key":"45419_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12640-016-9612-x","volume":"30","author":"O Solis","year":"2016","unstructured":"Solis, O., Garcia-Sanz, P., Herranz, A. S., Asensio, M. J. & Moratalla, R. L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum. Neurotox Res 30, 67\u201375, https:\/\/doi.org\/10.1007\/s12640-016-9612-x (2016).","journal-title":"Neurotox Res"},{"key":"45419_CR58","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.neuint.2013.02.015","volume":"62","author":"M Horio","year":"2013","unstructured":"Horio, M. et al. Decreased levels of free D-aspartic acid in the forebrain of serine racemase (Srr) knock-out mice. Neurochem Int 62, 843\u2013847, https:\/\/doi.org\/10.1016\/j.neuint.2013.02.015 (2013).","journal-title":"Neurochem Int"},{"key":"45419_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvw043","author":"T Ito","year":"2016","unstructured":"Ito, T. et al. Serine racemase is involved in d-aspartate biosynthesis. J Biochem. https:\/\/doi.org\/10.1093\/jb\/mvw043 (2016).","journal-title":"J Biochem"},{"key":"45419_CR60","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/jb\/mvj036","volume":"139","author":"HK Park","year":"2006","unstructured":"Park, H. K. et al. Potential role for astroglial D-amino acid oxidase in extracellular D-serine metabolism and cytotoxicity. J Biochem 139, 295\u2013304, https:\/\/doi.org\/10.1093\/jb\/mvj036 (2006).","journal-title":"J Biochem"},{"key":"45419_CR61","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/j.1460-9568.2007.05769.x","volume":"26","author":"L Verrall","year":"2007","unstructured":"Verrall, L. et al. d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur J Neurosci 26, 1657\u20131669, https:\/\/doi.org\/10.1111\/j.1460-9568.2007.05769.x (2007).","journal-title":"Eur J Neurosci"},{"key":"45419_CR62","doi-asserted-by":"crossref","unstructured":"Awad, H., Hubert, G. W., Smith, Y., Levey, A. I. & Conn, P. J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20, 7871\u20137879, doi:20\/21\/7871 [pii] (2000).","DOI":"10.1523\/JNEUROSCI.20-21-07871.2000"},{"key":"45419_CR63","doi-asserted-by":"crossref","unstructured":"Marino, M. J., Valenti, O. & Conn, P. J. Glutamate receptors and Parkinson\u2019s disease: opportunities for intervention. Drugs Aging 20, 377\u2013397, doi:2056 [pii] (2003).","DOI":"10.2165\/00002512-200320050-00006"},{"key":"45419_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1073858404269012","volume":"11","author":"EA Waxman","year":"2005","unstructured":"Waxman, E. A. & Lynch, D. R. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 11, 37\u201349, https:\/\/doi.org\/10.1177\/1073858404269012 (2005).","journal-title":"Neuroscientist"},{"key":"45419_CR65","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1038\/sj.emboj.7601840","volume":"26","author":"J Sasabe","year":"2007","unstructured":"Sasabe, J. et al. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J 26, 4149\u20134159, https:\/\/doi.org\/10.1038\/sj.emboj.7601840 (2007).","journal-title":"EMBO J"},{"key":"45419_CR66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.nbd.2013.10.016","volume":"62","author":"M Bourdenx","year":"2014","unstructured":"Bourdenx, M. et al. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson\u2019s disease and l-DOPA-induced dyskinesia. Neurobiol Dis 62, 307\u2013312, https:\/\/doi.org\/10.1016\/j.nbd.2013.10.016 (2014).","journal-title":"Neurobiol Dis"},{"key":"45419_CR67","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1093\/brain\/awr166","volume":"134","author":"G Charron","year":"2011","unstructured":"Charron, G. et al. Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain 134, 2321\u20132338, https:\/\/doi.org\/10.1093\/brain\/awr166 (2011).","journal-title":"Brain"},{"key":"45419_CR68","doi-asserted-by":"publisher","first-page":"e0181677","DOI":"10.1371\/journal.pone.0181677","volume":"12","author":"F Napolitano","year":"2017","unstructured":"Napolitano, F. et al. Decreased Rhes mRNA levels in the brain of patients with Parkinson\u2019s disease and MPTP-treated macaques. PLoS One 12, e0181677, https:\/\/doi.org\/10.1371\/journal.pone.0181677 (2017).","journal-title":"PLoS One"},{"key":"45419_CR69","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1172\/JCI59426","volume":"122","author":"G Porras","year":"2012","unstructured":"Porras, G. et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 122, 3977\u20133989, https:\/\/doi.org\/10.1172\/JCI59426 (2012).","journal-title":"J Clin Invest"},{"key":"45419_CR70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.nbd.2018.06.019","volume":"118","author":"E Rojo-Bustamante","year":"2018","unstructured":"Rojo-Bustamante, E. et al. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing\/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiol Dis 118, 64\u201375, https:\/\/doi.org\/10.1016\/j.nbd.2018.06.019 (2018).","journal-title":"Neurobiol Dis"},{"key":"45419_CR71","doi-asserted-by":"publisher","first-page":"e12322","DOI":"10.1371\/journal.pone.0012322","volume":"5","author":"E Santini","year":"2010","unstructured":"Santini, E. et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One 5, e12322, https:\/\/doi.org\/10.1371\/journal.pone.0012322 (2010).","journal-title":"PLoS One"},{"key":"45419_CR72","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2014.10.011","volume":"84","author":"M Shariatgorji","year":"2014","unstructured":"Shariatgorji, M. et al. Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections. Neuron 84, 697\u2013707, https:\/\/doi.org\/10.1016\/j.neuron.2014.10.011 (2014).","journal-title":"Neuron"},{"key":"45419_CR73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.nbd.2017.08.001","volume":"108","author":"J Stanic","year":"2017","unstructured":"Stanic, J. et al. Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiol Dis 108, 54\u201364, https:\/\/doi.org\/10.1016\/j.nbd.2017.08.001 (2017).","journal-title":"Neurobiol Dis"},{"key":"45419_CR74","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181\u2013184 (1992).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"45419_CR75","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18, 467\u2013486, https:\/\/doi.org\/10.1002\/mds.10459 (2003).","journal-title":"Mov Disord"},{"key":"45419_CR76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2217\/bmm.12.46","volume":"6","author":"M del Campo","year":"2012","unstructured":"del Campo, M. et al. Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: an update. Biomark Med 6, 419\u2013430, https:\/\/doi.org\/10.2217\/bmm.12.46 (2012).","journal-title":"Biomark Med"},{"key":"45419_CR77","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/jnr.21611","volume":"86","author":"P Devoto","year":"2008","unstructured":"Devoto, P. et al. 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. J Neurosci Res 86, 1647\u20131658, https:\/\/doi.org\/10.1002\/jnr.21611 (2008).","journal-title":"J Neurosci Res"},{"key":"45419_CR78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41537-017-0015-7","volume":"3","author":"T Nuzzo","year":"2017","unstructured":"Nuzzo, T. et al. Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. NPJ Schizophr 3, 16, https:\/\/doi.org\/10.1038\/s41537-017-0015-7 (2017).","journal-title":"NPJ Schizophr"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45419-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:36:07Z","timestamp":1671273367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45419-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45419"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45419-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8898"}}